Caly Chien serves as the Executive Director of Global Clinical Pharmacology at HUTCHMED, where he leverages over two decades of extensive experience in drug development to drive innovative solutions in oncology and immunology. His leadership has been pivotal in advancing clinical pharmacology development programs for...
Caly Chien serves as the Executive Director of Global Clinical Pharmacology at HUTCHMED, where he leverages over two decades of extensive experience in drug development to drive innovative solutions in oncology and immunology. His leadership has been pivotal in advancing clinical pharmacology development programs for key assets like fruquintinib (HMPL-013/FRUZAQLA) and surufatinib (HMPL-012), among others. Under his guidance, these projects have navigated complex regulatory landscapes, culminating in successful FDA approvals that have significantly impacted patient care.
Caly's expertise spans both early and late-stage clinical development, focusing on a diverse array of tumor types, including hematological malignancies such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), as well as solid tumors like colorectal cancer and neuroendocrine tumors. His strategic oversight ensures that clinical pharmacology considerations, including pharmacokinetics and pharmacometrics, are integrated into the drug development process, optimizing therapeutic efficacy and safety profiles.
In addition to his technical acumen, Caly excels in leading cross-functional teams across cultural boundaries, fostering collaboration that enhances innovation and accelerates project timelines. His strong communication skills and adeptness in regulatory submissions have been instrumental in aligning stakeholders and securing essential approvals. As he continues to spearhead HUTCHMED's clinical pharmacology initiatives, Caly's commitment to advancing novel therapies underscores his role as a key driver of progress in the pharmaceutical industry.
